High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
about
Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumorsHumoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parametersCancer vaccines: the next generation of tools to monitor the anticancer immune response.Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanomaMAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerPreferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancerPrinciples of adoptive T cell cancer therapy.Use of tumour-responsive T cells as cancer treatment.Induction of HCA587-specific antitumor immunity with HCA587 protein formulated with CpG and ISCOM in mice.Identifying source proteins for MHC class I-presented peptides.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapyA pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma.Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens.Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.Dendritic cell immunotherapy for breast cancer.Cancer-testis antigen MAGE-C2 binds Rbx1 and inhibits ubiquitin ligase-mediated turnover of cyclin E.Vaccination: role in metastatic melanoma.Identification and translational validation of novel mammaglobin-A CD8 T cell epitopesHarnessing DNA-induced immune responses for improving cancer vaccines.Immune correlates of melanoma survival in adoptive cell therapy.Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness.Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathwayMicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2.Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccinesInefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.Post-transplant adoptive T-cell immunotherapy.Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy.Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy.MAGE-A Antigens and Cancer Immunotherapy.Inducible expression of cancer-testis antigens in human prostate cancer.MAGEC2, an epithelial-mesenchymal transition inducer, is associated with breast cancer metastasis.Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes.
P2860
Q24615209-81531161-7CAC-4F0C-BD21-71D6C549B7E8Q24615872-9CF1A27D-15DA-4E16-AC43-79D9AA77F6CDQ24814450-A5F08BDF-9BA9-4D31-A561-B5943B9694EDQ28307216-3BA383C9-1CE4-454B-81C0-144390CC5ABAQ28478930-71A36A4D-2432-4949-9D63-A008292D5D9BQ33593103-9FF603FF-B7A1-4FDC-A097-4C24F60FD89FQ33873633-E712512D-9270-4EC3-AA67-2D5698C07F9BQ34003932-064EB92C-141D-4356-9786-8D3B18B1F767Q34285656-99116E3D-5C50-476E-96F3-E5B1988A79FEQ34448082-EEE04999-977A-44EA-8DC7-E3EA303DFABDQ34553385-6CA88028-CDEF-4D8A-9C78-47BF6CD48E23Q34627677-EE761007-02E5-4171-AB0F-B2AEC02D97D3Q34691545-F74D7FF9-D86C-4410-997C-25E6BAAA0F4EQ35012393-C8EECBB4-112A-45E4-9F47-4EEC024F90A5Q35201915-9BB243A7-1BEE-4480-B61D-291C6CDF90EEQ35540109-6EAA009B-4061-4064-80E5-9D5815E1D941Q35751259-0DFCEBE7-9C7D-426C-A297-E384571B5073Q35939427-059C9377-4425-468D-AF48-5FA75E050758Q36112645-6A99EB35-CD49-47BD-94B4-3A5D5F3C6D7EQ36239656-1C69E2F8-5862-40DA-92D3-B9A6C66975ECQ36471557-C0726E36-D566-4477-9D2E-4BC0C97C324CQ36480998-EEE3A5E1-EE9A-4DA2-9433-AB71EB8D5CC9Q36561664-B3273284-E824-48B0-B993-04BBA653D943Q36573868-FBBF28E9-52B7-4E89-A750-F454011F6EEAQ36623597-363C7421-E528-48B0-B09B-E76F01B1C81AQ36694866-68682869-57F0-4589-B860-19EA03DBCE54Q36694896-A16B5DC0-5654-41F7-A948-F158F7EF325AQ36742295-7F88E2F6-8F33-496C-B9D1-C992004C601CQ36786880-EE8B3CF3-5E3F-460A-9E19-89C8D9F73616Q36792348-955E7842-0D93-4911-BA75-5A1A198DB933Q37137360-9507F1C9-2617-46A6-A318-E39F0CB172F3Q37155831-25CCAEE6-1711-4DAF-ABD5-B7A60306E5B6Q37268318-95B63C68-442C-445F-918B-D421C3B6A797Q37611667-A1ED04B1-EA4D-48B4-83B1-0215B27ECAE6Q37628065-B45F6A1A-5157-4A37-86E3-A485F3E98E90Q37635491-78B4CAD0-3113-4DE5-AC56-02640570D19CQ37685379-94E9CC9F-1BD4-4EDE-9918-877DCD66B983Q37686238-09624CB6-0643-49D0-A10B-954F6C593581Q37699127-08952F5F-12CB-4CD9-886D-9E936E33B2DCQ37851050-505B6BEE-B7D7-4610-9277-A9C336AB10C8
P2860
High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
High frequency of antitumor T ...... ccination with tumor antigens.
@ast
High frequency of antitumor T ...... ccination with tumor antigens.
@en
type
label
High frequency of antitumor T ...... ccination with tumor antigens.
@ast
High frequency of antitumor T ...... ccination with tumor antigens.
@en
prefLabel
High frequency of antitumor T ...... ccination with tumor antigens.
@ast
High frequency of antitumor T ...... ccination with tumor antigens.
@en
P2093
P2860
P356
P1476
High frequency of antitumor T ...... ccination with tumor antigens.
@en
P2093
Bernard Lethé
Catherine Germeau
Christophe Lurquin
Emmanuelle Henry
Etienne De Plaen
Francesca Schiavetti
Francis Brasseur
Nathalie Vigneron
Pierre G Coulie
Thierry Boon
P2860
P304
P356
10.1084/JEM.20041379
P407
P577
2005-01-01T00:00:00Z